| 证券代码：603716 | 证券简称：塞力医疗 | 公告编号：2025-075 | | --- | --- | --- | | 债券代码：113601 | 债券简称：塞力转债 | | 塞力斯医疗科技集团股份有限公司 关于取消监事会、变更公司注册资本并修订《公司章程》 及修订和制定部分管理制度的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 为全面贯彻落实法律法规及监管要求，进一步提升公司治理水平，塞力斯医 疗科技集团股份有限公司（以下简称"公司"）根据《中华人民共和国公司法》 《上海证券交易所股票上市规则》《上海证券交易所上市公司自律监管指引第 1 号——规范运作》《上市公司章程指引》等最新相关法律法规的调整，并结合公 司实际情况，对《公司章程》及有关管理制度部分条款进行修订，同时新制定部 分管理制度。 一、取消监事会情况 为进一步完善公司结构、推动公司规范运作，根据相关法律法规规定，公司 拟取消监事会，监事会相关职权由董事会审计委员会承接，同时公司的《监事会 议事规则》随之废止。 在公司股东大会审议通过取消监事会前 ...

塞力医疗(603716.SH)公告称，2025年上半年实现营业收入5.84亿元，同比下降40.20%；实现归属于上 市公司股东的净利润-5611.92万元。 ...

Company Overview - Seer Medical Technology Group Co., Ltd. is located in Wuhan, Hubei Province, established on February 23, 2004, and listed on October 31, 2016 [2] - The company's main business includes centralized marketing and service for medical testing, agency for in vitro diagnostic products, and R&D, production, and sales of self-developed in vitro diagnostic products [2] - The revenue composition is as follows: centralized SPD 45.10%, centralized IVD 33.43%, and pure sales 21.47% [2] Financial Performance - As of March 31, the number of shareholders is 46,600, an increase of 52.46% compared to the previous period; the average circulating shares per person is 4,099, a decrease of 34.40% [2] - For the first quarter of 2025, the company achieved operating revenue of 287 million yuan, a year-on-year decrease of 40.75%; the net profit attributable to the parent company was -14.32 million yuan, a year-on-year decrease of 553.66% [2] Stock Performance - On August 28, the stock price of Seer Medical fell by 2.02%, trading at 32.48 yuan per share, with a transaction volume of 319 million yuan and a turnover rate of 5.05%, resulting in a total market value of 6.204 billion yuan [1] - Year-to-date, the stock price has increased by 349.86%, with a 13.37% increase over the last five trading days, an 8.19% increase over the last 20 days, and a 165.36% increase over the last 60 days [1] - The company has appeared on the daily trading leaderboard 37 times this year, with the most recent appearance on August 26, where the net buying on the leaderboard was 146 million yuan, accounting for 18.85% of the total trading volume [1] Dividend Information - Since its A-share listing, Seer Medical has distributed a total of 27.0741 million yuan in dividends, with no dividends distributed in the last three years [3]

New Stock Offerings - Shenke Co., Ltd. (002633) has an offer period from July 29, 2025, to August 27, 2025[1] - Fushun Special Steel (600399) has an offer period from August 12, 2025, to September 10, 2025[1] - ST Gaohong (000851) has an announcement on August 26, 2025[1] Market Volatility - Great Wall Military Industry (601606) reported severe abnormal fluctuations on August 14, 2025[1] - Dongxin Co., Ltd. (688110) had an announcement on August 16, 2025, regarding market conditions[1] - Changfei Optical Fiber (601869) has an announcement dated August 27, 2025, related to market performance[1] Company Announcements - ST Dehao (002005) has an announcement on August 27, 2025, regarding its market status[1] - China Satellite (600118) announced updates on August 27, 2025[1] - ST Yizhong (603389) has an announcement dated August 26, 2025, regarding its market activities[1]

Market Overview - The pharmaceutical commercial sector experienced a decline of 2.71% on August 27, with Saily Medical leading the drop [1] - The Shanghai Composite Index closed at 3800.35, down 1.76%, while the Shenzhen Component Index closed at 12295.07, down 1.43% [1] Individual Stock Performance - Saily Medical (603716) closed at 33.15, down 8.93% with a trading volume of 484,700 shares and a transaction value of 1.671 billion [1] - Other notable declines included HeLiang China (603122) down 5.15%, YaoYigou (300937) down 5.10%, and Guofa Shares (600538) down 4.98% [1] - The overall net outflow of main funds from the pharmaceutical commercial sector was 543 million, while retail investors saw a net inflow of 361 million [1] Fund Flow Analysis - Jiuzhoutong (600998) had a main fund net inflow of 11.8 million, accounting for 18.23% of its total [2] - Dacilin (603233) saw a main fund net inflow of 29.97 million, representing 15.70% [2] - The overall trend indicates a mixed sentiment with main funds withdrawing while retail investors are actively buying [2]

Group 1 - A-share market sees a decline in several innovative drug concept stocks, with Yuekang Pharmaceutical dropping over 10% [1] - Guangshengtang falls by 8%, while Lifang Pharmaceutical and Haishike decrease by over 7% [1] - Saili Medical declines by over 6%, and Huiyu Pharmaceutical drops by over 5% [1] - Jingxin Pharmaceutical experiences a decline of over 4%, with Shutaishen, Haiteshengwu, and Xinlitai all falling by over 3% [1]

登录新浪财经APP 搜索【信披】查看更多考评等级 塞力斯医疗科技集团股份有限公司 股票交易异常波动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 塞力斯医疗科技集团股份有限公司（以下简称"公司"）股票连续3个交易日内日收盘价格涨幅偏离值 累计超过20%，根据《上海证券交易所交易规则》的有关规定，属于股票交易异常波动情形。 ● 经公司自查，并向控股股东赛海（上海）健康科技有限公司（以下简称"赛海科技"）及实际控制人温 伟先生发函核实，截至本公告披露日，控股股东及实际控制人不存在应披露而未披露的重大信息，包括 但不限于重大资产重组、股份发行、重大交易类事项、业务重组、股份回购、破产重整、重大业务合 作、引进战略投资者等重大事项。 ● 风险提示详见本公告"三、相关风险提示"，公司倡导价值投资并专注于主业的发展，敬请广大投资者 注意二级市场交易风险，理性决策，审慎投资。 一、股票交易异常波动的具体情况 公司股票连续3个交易日内日收盘价格涨幅偏离值累计超过20%，根据《上海证券交易所交易规则》的 有关规定，属于 ...

Core Viewpoint - The company, Sely Medical, announced that its stock price has deviated significantly, with a cumulative increase of over 20% in the last three trading days, indicating abnormal trading fluctuations [1] Company Operations - The company conducted a self-examination and confirmed that all production and operational activities are normal [1] - There have been no significant changes in the market environment or industry policies affecting the company [1] - The internal production and operational order remains normal [1] Disclosure of Information - The company stated that there are no major events that could impact the abnormal fluctuations in stock trading prices [1] - There are no undisclosed significant information that should have been disclosed [1]

| 证券代码：603716 | 证券简称：塞力医疗 | 公告编号：2025-071 | | --- | --- | --- | | 债券代码：113601 | 债券简称：塞力转债 | | 塞力斯医疗科技集团股份有限公司 股票交易异常波动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 塞力斯医疗科技集团股份有限公司（以下简称"公司"）股票连续3个交 易日内日收盘价格涨幅偏离值累计超过20%，根据《上海证券交易所交易规则》 的有关规定，属于股票交易异常波动情形。 经公司自查，并向控股股东赛海（上海）健康科技有限公司（以下简称 "赛海科技"）及实际控制人温伟先生发函核实，截至本公告披露日，控股股东 及实际控制人不存在应披露而未披露的重大信息，包括但不限于重大资产重组、 股份发行、重大交易类事项、业务重组、股份回购、破产重整、重大业务合作、 引进战略投资者等重大事项。 风险提示详见本公告"三、相关风险提示"，公司倡导价值投资并专注 于主业的发展，敬请广大投资者注意二级市场交易风险，理性决策，审慎投资。 一、股票交 ...

002082 万邦德 9.97 8.58 11095.60 688166 博瑞医药 0.00 2.11 7574.49 沪指8月26日下跌0.39%，申万所属行业中，今日上涨的有17个，涨幅居前的行业为农林牧渔、美容护 理，涨幅分别为2.62%、2.04%。跌幅居前的行业为医药生物、非银金融，跌幅分别为1.09%、1.06%。 医药生物行业位居今日跌幅榜首位。 资金面上看，两市主力资金全天净流出688.55亿元，主力资金净流入的行业仅有2个，美容护理行业净 流入资金2.76亿元;农林牧渔行业净流入资金2.57亿元。 主力资金净流出的行业有29个，有色金属行业主力资金净流出规模居首，全天净流出资金107.12亿元， 其次是医药生物行业，净流出资金为82.54亿元，净流出资金较多的还有国防军工、非银金融、电力设 备等行业。 医药生物行业今日下跌1.09%，全天主力资金净流出82.54亿元，该行业所属的个股共474只，今日上涨 的有151只，涨停的有3只;下跌的有307只。以资金流向数据进行统计，该行业资金净流入的个股有168 只，其中，净流入资金超5000万元的有9只，净流入资金居首的是康德莱，今日净流入资金1. ...